Pembrolizumab is a type of immunotherapy medication that helps your immune system fight cancer cells. It works by blocking a protein called PD-1, which normally prevents T-cells (immune cells) from attacking cancer cells. By blocking this protein, pembrolizumab allows your immune system to better recognize and destroy cancer cells, particularly in Hodgkin Lymphoma.

P-BrECADD is a combination chemotherapy regimen that contains multiple medications working together to treat Hodgkin Lymphoma. This treatment combines different drugs that attack cancer cells in various ways to make the treatment more effective. It is administered through intravenous infusion in cycles.

Note: The treatment plan also includes radiotherapy as a standard part of care, which uses targeted radiation to destroy cancer cells in specific areas of the body.

Classic Hodgkin Lymphoma – A type of blood cancer that begins in the lymphatic system, specifically affecting a type of white blood cells called lymphocytes. The disease typically starts in the lymph nodes and can spread progressively through the lymphatic system to other parts of the body. It is characterized by the presence of abnormal cells called Reed-Sternberg cells, which are much larger than normal lymphocytes. The condition usually develops in a predictable pattern, moving from one group of lymph nodes to another. In advanced stages, it can spread to organs outside the lymphatic system.